Keywords: renagel, sales, leap, genzyme, general, having, recently
Renagel sales leap at Genzyme General
Article | 18 March 2002
Having recently reported a fourth-quarter 2001 revenue rise of 30% to$264 million (Marketletter January 21), Genzyme General, a division of Genzyme Corp, has ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
